On January 28, 2025 Curium, a world leader in nuclear medicine, reported that in Estonia, Finland, Latvia, and Sweden, PYLCLARI is now available for patients with prostate cancer (Press release, Curium Pharma, JAN 28, 2025, View Source [SID1234649904]). PYLCLARI (INN: Piflufolastat (18F) also known as (18F)-DCFPyL) is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Primary staging of patients with high-risk prostate cancer prior to initial curative therapy
To localize recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent
Benoit Woessmer, CEO Europe commented, "The availability of PYLCLARI in Estonia, Finland, Latvia, and Sweden is an important milestone for patients with prostate cancer, since it is vital that we continue to improve the choice of diagnostic radiopharmaceuticals available to physicians to better diagnose and monitor prostate cancer. As we continue to redefine the experience of cancer through our trusted legacy in nuclear medicine, we are proud that the availability of PYLCLARI continues to grow and now covers eleven European countries."
In countries across the Nordic and Baltic regions, prostate cancer is one of the most common cancers among men with around 25,000 new cases diagnosed regionally every year according to the European Cancer Information System. PYLCLARI is being produced by Curium at its facilities in Helsinki, Finland – ensuring distribution to Estonia, Finland, Latvia, and Sweden.
For more information about PYLCLARI: www.pylclari.com
In the U.S., Lantheus received approval for PYLARIFY (Piflufolastat F 18 Injection) from the Food and Drug Administration (FDA) in May 2021. It is the #1 utilized PSMA PET agent in the U.S. market. The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018.